Q1 2025 EPS Estimates for Avantor, Inc. Increased by Analyst (NYSE:AVTR)

Avantor, Inc. (NYSE:AVTR) – Equities research analysts at Zacks Research raised their Q1 2025 earnings estimates for shares of Avantor in a research report issued on Tuesday, June 25th. Zacks Research analyst D. Dey now forecasts that the company will earn $0.28 per share for the quarter, up from their prior forecast of $0.27. The consensus estimate for Avantor’s current full-year earnings is $1.01 per share. Zacks Research also issued estimates for Avantor’s Q2 2025 earnings at $0.26 EPS and Q1 2026 earnings at $0.32 EPS.

A number of other research analysts have also recently commented on AVTR. Evercore ISI boosted their price target on Avantor from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Avantor from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Thursday, April 18th. Robert W. Baird cut their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, April 29th. Finally, Barclays lifted their price objective on shares of Avantor from $27.00 to $30.00 and gave the company an “overweight” rating in a research note on Wednesday, April 10th. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, Avantor has an average rating of “Moderate Buy” and an average target price of $26.71.

Avantor Stock Performance

NYSE:AVTR opened at $21.95 on Thursday. The company has a market cap of $14.91 billion, a price-to-earnings ratio of 56.28, a PEG ratio of 2.24 and a beta of 1.35. Avantor has a fifty-two week low of $16.63 and a fifty-two week high of $26.16. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.05 and a current ratio of 1.61. The stock has a fifty day moving average price of $23.90 and a 200-day moving average price of $23.82.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Friday, April 26th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.02. Avantor had a return on equity of 13.01% and a net margin of 3.79%. The business had revenue of $1.68 billion during the quarter, compared to analysts’ expectations of $1.68 billion. During the same period in the previous year, the company posted $0.29 earnings per share. The firm’s revenue for the quarter was down 5.6% compared to the same quarter last year.

Institutional Trading of Avantor

Several institutional investors have recently added to or reduced their stakes in the stock. Mariner LLC increased its position in shares of Avantor by 17.3% during the third quarter. Mariner LLC now owns 42,025 shares of the company’s stock worth $886,000 after buying an additional 6,196 shares during the period. Northern Trust Corp raised its position in shares of Avantor by 9.0% in the 3rd quarter. Northern Trust Corp now owns 4,129,447 shares of the company’s stock worth $87,049,000 after acquiring an additional 342,553 shares in the last quarter. Treasurer of the State of North Carolina lifted its stake in shares of Avantor by 0.4% in the 3rd quarter. Treasurer of the State of North Carolina now owns 313,496 shares of the company’s stock valued at $6,608,000 after purchasing an additional 1,187 shares during the period. Tower Research Capital LLC TRC grew its stake in Avantor by 170.4% during the third quarter. Tower Research Capital LLC TRC now owns 24,722 shares of the company’s stock worth $521,000 after purchasing an additional 15,580 shares during the period. Finally, Bank of Nova Scotia lifted its stake in Avantor by 18.1% in the third quarter. Bank of Nova Scotia now owns 16,024 shares of the company’s stock valued at $338,000 after buying an additional 2,455 shares during the period. 95.08% of the stock is currently owned by institutional investors.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.